Development of Hepatocyte‐like Cell Derived from Human Induced Pluripotent Stem cell as a Host for Clinically Isolated Hepatitis C Virus. (14th August 2017)

• Record Type: Journal Article
• Authors: Sa‐ngiamsuntorn, Khanit; Hongeng, Suradej; Wongkajornsilp, Adisak
• Editors: Bhatia, Mick; Elefanty, Andrew G.; Fisher, Susan J.; Patient, Roger; Schlaeger, Thorsten; Snyder, Evan Y.
• Is Part Of: Current protocols in stem cell biology. Volume 42(2018)
• Page Start: 4A.13.1
• Page End: 4A.13.34
• Publication Date: 2017-08-14
• Subjects: cellular reprogramming -- hepatitis C virus (HCV) -- hepatocyte‐like cell (HLC) -- induced pluripotent stem cell (iPSC) -- mesenchymal stem cell (MSC) -- JFH‐1 -- HCVcc -- HCVser; Stem cells -- Laboratory manuals; Stem cells -- Physiology; Stem Cells; Stem cells; Laboratory Manual; Laboratory manuals; 571.5
• DOI: 10.1002/cpsc.35
• Languages: English
• ISSNs: 1941-7322

Abstract

Abstract: This unit describes protocols to develop hepatocyte‐like cells (HLCs) starting from mesenchymal stem cells (MSCs) as a natural host for hepatitis C virus (HCV). These include the preparation of MSCs from bone marrow, the reprogramming of MSCs into induced pluripotent stem cells (iPSCs), and the differentiation of iPSCs into HLCs. This unit also incorporates the characterization of the resulting cells at each stage. Another section entails the preparations of HCV. The sources of HCV are either the clinically isolated HCV (HCVser) and the conventional JFH‐1 genotype. The last section is the infection protocol coupled with the measurement of viral titer. © 2017 by John Wiley & Sons, Inc.